Though the details of its work in AI and robotics have been kept under wraps, Mendaera also sees its new telehealth platform supporting a broader goal of alleviating workforce shortages and burnout. (Avail Medsystems)
Website – https://www.mendaera.com/
Website – https://www.avail.io/
Additional reading – My written interview with the Avail CEO in 2020 – 6 Questions with Daniel Hawkins, CEO at Avail, who is transforming the way orthopedic procedures will be supported.
Additional listening – My podcast interview with the Avail CEO in 2020
Mendaera acquires the Avail Medsystems assets for undisclosed amount.
During the height of the social distancing era of the COVID-19 pandemic, Avail Medsystems was able to raise $100 million in venture capital funding with a simple pitch to hospitals and the medtech industry: virtual surgery consults.
The former Fierce 15 winner’s goal was to connect clinicians with manufacturers and medical advisors through a live telehealth platform—an objective it had pursued even before the coronavirus’ international spread closed up operations after being founded in 2017 with the hope of getting more sales reps into more surgical centers, digitally.
But as in-person came back into vogue, Avail found itself unable to adjust to the return of the “old normal.” The company abruptly shut down operations last November, after failing to close a new round of VC financing.
Now, Avail’s telepresence technology has found a new home with the surgical robotics startup Mendaera—a Silicon Valley outfit that aims to use the portfolio to support its approach to image-guided, needle-based procedures.
“The acquisition will allow us to work more closely with the clinical community and accelerate the development and adoption of our platform,” Mendaera co-founder and CEO Josh DeFonzo said in a statement. The cost of the transaction was not disclosed.
“More importantly, the combination of robotics and telepresence technology will amplify what healthcare providers are able to do for their patients, ultimately improving care by unlocking new care delivery models,” added DeFonzo, who previously served as the chief operating officer of Auris Health, before it was acquired by Johnson & Johnson in a $3.4 billion deal for its Monarch bronchoscopy robot.
Mendaera also sees its new telehealth platform supporting its broader goal of helping to alleviate workforce shortages and clinician burnout. The company raised $24 million in an August 2023 series A round that was led by Lux Capital and also backed by Auris and Intuitive Surgical founder Fred Moll, among others.
Though the details of its work in artificial intelligence and robotics have so far been kept under wraps, Mendaera previously announced a partnership with the handheld ultrasound developer Butterfly Network, to integrate its imaging hardware for real-time guidance.
“We believe that healthcare systems need solutions that will drive far greater efficiency and equity in the U.S. and abroad,” said Peter Hebert, co-founder and managing partner at Lux Capital, which had also made early investments in Avail. “This acquisition uniquely positions Mendaera to deliver scalable and transformative technology that will create a better future for patients and providers alike.”
Stealthy startup Mendaera is developing a fist-sized medical robot — with Dr. Fred Moll’s support
March 19, 2024 By Jim Hammerand Leave a Comment
The veil is starting to lift on medical robotics startup Mendaera as it exits stealth mode and heads toward regulatory submission with a design freeze on its first system and verification and validation imminent.
San Mateo, California–based Mendaera was founded by two former Auris Health leaders and has financial support from Dr. Fred Moll, the Auris and Intuitive Surgical co-founder who is known as the father of robotic surgery.
“Among the innovators in the field, Mendaera’s efforts to make robotics commonplace earlier in the healthcare continuum are unique and can potentially change the future of care delivery,” Moll said in a news release announcing his investment in the startup.
But Mendaera isn’t a surgical robotics developer. Instead, they’re working on technology that combines robotics, artificial intelligence and real-time imaging in a compact device “no bigger than your fist” for procedures including percutaneous instruments.
That’s according to Mendaera co-founder and CEO Josh DeFonzo, who offered new details about his startup’s technology and goals in an exclusive interview as he announced the acquisition of operating room telepresence technology developed by Avail Medsystems. (Avail was founded by former Intuitive Surgical and Shockwave Medical leader Daniel Hawkins, who’s now CEO at MRI automation software startup Vista.ai.)
Mendaera co-founder and CEO Josh DeFonzo [Photo courtesy of Mendaera]
“We’re a very different form factor of robot that focuses on what I’ll describe as gateway procedures,” DeFonzo said. “… It’s a different category of robots that we don’t believe the market has seen before [as] we’re designing and developing it.”
Those procedures include vascular access for delivery of devices or therapeutic agents, access to organs for surgical or diagnostics purposes, and pain management procedures such as regional anesthesia, neuraxial blocks and chronic pain management. DeFonzo declined to go into too much detail about specific procedures because the product is still in the development stage.
“The procedures that we are going after are those procedures that involve essentially a needle or a needle-like device and real-time imaging, and as such, there are specific procedures that we think the technology will perform very well at,” DeFonzo said. “However, the technology is also designed to be able to address any suite of procedures that use those two common denominators: real-time imaging and a percutaneous instrument. And the reason that’s an important point to make is that oftentimes, when you are a specialist who performs these procedures, you don’t perform just one. You perform a number of procedures: central venous catheters (CVCs), peripherally inserted central catheter (PICC) lines, regional anesthetic blocks that are in the interscalene area or axial blocks. The technology is really designed to enable specialists — of whom there are many — the ability to perform these procedures more consistently with a dramatically lower learning curve.”
Preclinical testing has shown the technology has improved accuracy and efficiency compared to freehand techniques, regardless of the individual’s skill level, DeFonzo said User research spanned around 1,000 different healthcare providers ranging from emergency medicine, interventional radiology, licensed medical doctors, nurse practitioners and physician’s assistants.
“It seems to be very stable across user types,” DeFonzo said. “So whether somebody is a novice, of intermediate skill level or advanced, the robot is a great leveler in terms of being able to provide consistent outcomes. Whereas when you look at the same techniques performed freehand, the data generally tracks with what you would expect: lesser skilled people are less accurate, more experienced people are more accurate. But even in that most skilled category, we do find that the robot makes a fairly remarkable improvement on accuracy and timeliness of intervention.”
Butterfly Network won FDA 510(k) clearance in 2017 for the world’s first ultrasound-on-a-chip imaging system, the Butterfly iQ for iPhone. [Photo courtesy of Butterfly Network]
Last year, the startup expanded into a production facility to accommodate growth and volume manufacturing for the product’s launch, and said its system will be powered by handheld ultrasound developer Butterfly Network’s Ultrasound-on-Chip technology.
Mendaera’s aim is to eventually deploy these systems “to the absolute edge of healthcare,” DeFonzo said, starting with hospitals, ambulatory surgical centers and other procedural settings, and then pushing to alternative care sites and primary care clinics as evidence builds to support the technology.
“The entire mission for the company is to ensure essentially that high-quality intervention is afforded to every patient at every care center at every encounter,” he said. “We want to be able to push that as far to the edge of healthcare as possible, and that’s certainly something we aim to do over time, but it’s not our starting point explicitly. … As a practical starting point, however, we do see ourselves working in the operating room, in the interventional radiology suite, and likely in cath labs to facilitate these gateway procedures, the access that is afforded adjacent to a larger intervention.”
Mendaera anticipates submitting its system to the FDA for review through the 510(k) pathway by the end of 2024 with the goal of offering the product clinically in 2025.
“What we really want to do with this technology is make sure that we’re leveraging not just technological trends, but really important forces in the space — robotics, imaging and AI — to dramatically improve access to care,” DeFonzo said. “… Whether you’re talking about something as basic as a vascular access procedure or something as complex as transplant surgery or neurosurgery, we need to leverage technology to improve patient experience, we need to leverage technology to help hospitals become more financially sustainable, ultimately improving the healthcare system as we do it. So our vision was to utilize technology to provide solutions that aggregate across many millions if not tens and hundreds of millions of procedures to make a ubiquitous technology that really helps benefit our healthcare system.”
The company R&D group will work with employees from Avail on how to best add the telepresence technology to the mix.
“We see a lot of power in what the Avail team has built,” DeFonzo said. “Bringing that alongside robotic technology, our imaging partnerships and AI, we think that we’ve got a really good opportunity to digitize to a further extent not only expertise in the form of the robot, but clinical judgment, like how do you ensure that the right clinician and his or her input is present ahead of technologies like artificial intelligence that hopefully augment all users in an even more scalable way.”